CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Aurora kinase A (AURKA) is aberrantly expressed in acute myelogenous leukemia (AML).
• CD34(+) /CD38(-) AML cells, enriched for leukemia stem cells, exhibit resistance to cytarabine therapy.
• Identifying therapeutic targets in these resistant AML cells is crucial for effective treatment.

Purpose of the Study:

• To investigate AURKA as a potential therapeutic target in CD34(+) /CD38(-) AML cells.
• To evaluate the efficacy of AURKA inhibition in targeting chemotherapy-resistant AML stem cells.

Main Methods:

• Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) to quantify AURKA expression in patient-derived AML cells and healthy controls.
• Pharmacological inhibition of AURKA using MLN8237 and genetic inhibition using short hairpin RNA (shRNA).
• Assessment of proliferation, self-renewal, apoptosis, and in vivo engraftment of AML cells following AURKA blockade.

Main Results:

• CD34(+) /CD38(-) AML cells express significantly higher levels of AURKA compared to CD34(+) /CD38(+) AML cells and normal hematopoietic stem/progenitor cells.
• AURKA inhibition via MLN8237 or shRNA markedly reduced proliferation, impaired self-renewal, and induced apoptosis in CD34(+) /CD38(-) AML cells.
• Inhibition of AURKA significantly reduced the engraftment of CD34(+) /CD38(-) AML cells in mice and prolonged survival, suggesting a critical role in leukemia stem cell function.

Conclusions:

• AURKA is a promising molecular target for eliminating chemotherapy-resistant CD34(+) /CD38(-) AML cells.
• Targeting AURKA demonstrates potential for improving therapeutic outcomes in AML by eradicating leukemia stem cells.